Trajectories of Antiretroviral Therapy Adherence and Virologic Failure in Women With HIV in the United States

Supplemental Digital Content is Available in the Text. Background: Women with HIV (WHIV) in the United States face many challenges with adherence to antiretroviral therapy (ART), and suboptimal adherence often leads to virologic failure. This study aimed to determine the association between ART adherence trajectories and the risk of virologic failure. Methods: We included WHIV (aged 18 years or older) enrolled in the Women's Interagency HIV Study in the United States from April 2014 to September 2019 who had at least 2 consecutive measurements of HIV RNA and ≥3 measurements of self-reported adherence. Group-based trajectory modeling was used to identify adherence trajectories. Cox proportional hazard ratios were used to measure the association. Main Outcome Measure: Virologic failure was defined as HIV RNA ≥200 copies/mL at 2 consecutive visits. Results: We included 1437 WHIV (median age 49 years). Of all women, 173 (12.0%) experienced virologic failure. Four adherence trajectories were identified, namely “consistently high” (26.3%), “moderate increasing” (9.5%), “moderate decreasing” (30.6%), and “consistently low” (33.5%). Women in the consistently low adherence group consumed alcohol and experienced depression more than other groups. Compared with the “consistently high” trajectory, the risk of virologic failure was higher among women with “consistently low” [adjusted hazard ratio (aHR) 2.8; 95% confidence interval (CI): 1.6 to 4.9; P < 0.001] and “moderate decreasing” adherence trajectories (aHR 1.8; 95% CI: 1.0 to 3.2; P = 0.04), but it was similar to those with “moderate increasing” adherence trajectory (aHR 1.0; 95% CI: 0.4 to 2.5; P = 0.94). Conclusions: Adherence to ART remains a challenge among WHIV. Multilevel behavioral interventions to address poor adherence, alcohol consumption, and depression are needed.

[1]  L. Brown,et al.  A Review of Interventions to Enhance HIV Medication Adherence , 2021, Current HIV/AIDS Reports.

[2]  J. Mermin,et al.  Estimated Annual Number of HIV Infections ─ United States, 1981–2019 , 2021, MMWR. Morbidity and mortality weekly report.

[3]  O. Mgbere,et al.  Evaluation of the Sociodemographic, Behavioral and Clinical Influences on Complete Antiretroviral Therapy Adherence Among HIV-Infected Adults Receiving Medical Care in Houston, Texas , 2021, HIV/AIDS.

[4]  E. Miller,et al.  Mental Health in Women Living With HIV: The Unique and Unmet Needs , 2021, Journal of the International Association of Providers of AIDS Care.

[5]  E. Weld Limits of Detection and Limits of Infection: Quantitative HIV Measurement in the Era of U = U. , 2020, The journal of applied laboratory medicine.

[6]  D. Holdford,et al.  Medication Adherence Trajectories: A Systematic Literature Review , 2020, Journal of managed care & specialty pharmacy.

[7]  R. Savage,et al.  Feasibility, acceptability, and preliminary impact of telemedicine-administered cognitive behavioral therapy for adherence and depression among African American women living with HIV in the rural South , 2020, Journal of health psychology.

[8]  L. Mesana,et al.  Antiretroviral Adherence, Drug Resistance, and the Impact of Social Determinants of Health in HIV-1 Patients in the US , 2020, AIDS and Behavior.

[9]  J. Haberer,et al.  Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions , 2020, Current HIV/AIDS Reports.

[10]  Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV , 2020 .

[11]  C. Armon,et al.  Disparities in Viral Suppression and Medication Adherence among Women in the USA, 2011–2016 , 2019, AIDS and Behavior.

[12]  Mardge H. Cohen,et al.  Viremia Trajectories of HIV in HIV-Positive Women in the United States, 1994-2017 , 2019, JAMA network open.

[13]  Jennifer A. Pellowski,et al.  A Systematic Review and Meta-analysis of Antiretroviral Therapy (ART) Adherence Interventions for Women Living with HIV , 2018, AIDS and Behavior.

[14]  G. Wagner,et al.  Antiretroviral Adherence Trajectories Among Black Americans Living with HIV , 2018, AIDS and Behavior.

[15]  Gina Wingood,et al.  Cohort Profile: The Women's Interagency HIV Study (WIHS). , 2018, International journal of epidemiology.

[16]  M. Friend,et al.  Estimated HIV incidence and prevalence in the United States 2010–2015 , 2018 .

[17]  P. Anderson,et al.  Inflammation and pharmacokinetics: potential implications for HIV-infection , 2017, Expert opinion on drug metabolism & toxicology.

[18]  Aaron N. Winn,et al.  The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer , 2016, Pharmacoepidemiology and drug safety.

[19]  S. Eholie,et al.  Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question , 2016, AIDS Research and Therapy.

[20]  V. Rivera-Amill,et al.  Impact of Depression and Inflammation on the Progression of HIV Disease , 2016, Journal of clinical & cellular immunology.

[21]  S. Perera,et al.  Trajectories of Diabetes Medication Adherence and Hospitalization Risk: A Retrospective Cohort Study in a Large State Medicaid Program , 2016, Journal of General Internal Medicine.

[22]  W. Andiman,et al.  Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time. , 2016, Journal of AIDS & clinical research.

[23]  Jeffrey N. Martin,et al.  Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda , 2015, Journal of acquired immune deficiency syndromes.

[24]  A. Carrico,et al.  Unhealthy Alcohol Use is Associated with Monocyte Activation Prior to Starting Antiretroviral Therapy. , 2015, Alcoholism, clinical and experimental research.

[25]  T. Brennan,et al.  Association between trajectories of statin adherence and subsequent cardiovascular events , 2015, Pharmacoepidemiology and drug safety.

[26]  Blair T. Johnson,et al.  Health Behavior Change Models for HIV Prevention and AIDS Care: Practical Recommendations for a Multi-Level Approach , 2014, Journal of acquired immune deficiency syndromes.

[27]  K. Arheart,et al.  Tobacco Smoking Increases Immune Activation and Impairs T-Cell Function in HIV Infected Patients on Antiretrovirals: A Cross-Sectional Pilot Study , 2014, PloS one.

[28]  G. Peterson,et al.  Barriers and Facilitators of Adherence to Antiretroviral Drug Therapy and Retention in Care among Adult HIV-Positive Patients: A Qualitative Study from Ethiopia , 2014, PloS one.

[29]  Mardge H. Cohen,et al.  Understanding the Disparity: Predictors of Virologic Failure in Women Using Highly Active Antiretroviral Therapy Vary by Race and/or Ethnicity , 2013, Journal of acquired immune deficiency syndromes.

[30]  Daniel S. Nagin,et al.  A Note on a Stata Plugin for Estimating Group-based Trajectory Models , 2012 .

[31]  P. Harrigan,et al.  Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level , 2010, Journal of acquired immune deficiency syndromes.

[32]  Daniel S Nagin,et al.  Group-based trajectory modeling in clinical research. , 2010, Annual review of clinical psychology.

[33]  A. Applebaum,et al.  Gender and Other Psychosocial Factors as Predictors of Adherence to Highly Active Antiretroviral Therapy (HAART) in Adults with Comorbid HIV/AIDS, Psychiatric and Substance-related Disorder , 2009, AIDS and Behavior.

[34]  J. Parsons,et al.  Motivational Interviewing and Cognitive-Behavioral Intervention to Improve HIV Medication Adherence Among Hazardous Drinkers: A Randomized Controlled Trial , 2007, Journal of acquired immune deficiency syndromes.

[35]  W. Hauck,et al.  Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users , 2003, Journal of General Internal Medicine.

[36]  Ann E. Kurth,et al.  Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management , 2006, AIDS and Behavior.

[37]  M. Young,et al.  The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench , 2005, Clinical Diagnostic Laboratory Immunology.

[38]  Marcus H Snow,et al.  HIV viral suppression in the era of antiretroviral therapy , 2003, Postgraduate medical journal.

[39]  Joseph Feldman,et al.  The Women's Interagency HIV Study , 1998 .

[40]  L. Radloff The CES-D Scale: A Self-Report Depression Scale for Research in the General Population — Source link , 2022 .